PlumX Metrics
Embed PlumX Metrics

Clinical pharmacokinetics of dorzolamide

Clinical Pharmacokinetics, ISSN: 0312-5963, Vol: 41, Issue: 3, Page: 197-205
2002
  • 42
    Citations
  • 0
    Usage
  • 39
    Captures
  • 3
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    42
  • Captures
    39
  • Mentions
    3
    • News Mentions
      2
      • News
        2
    • References
      1
      • Wikipedia
        1

Most Recent News

Development and Validation of Stability Indicting HPLC Method for the Separation and Simultaneous Analysis of Timolol, Dorzolamide and Latanoprost Inophthalmic formulations

A. Krishnamanjari Pawar1*, Chandana Mannepalli2 1Associate Professor, A. U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India. 2Research Scholar, A. U. College of Pharmaceutical Sciences,

Review Description

Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. After absorption via the cornea and stroma, it inhibits carbonic anhydrase in the ciliary process, which leads to a reduction of aqueous humour production and therefore to the desired therapeutic effect. In the systemic circulation, dorzolamide is bound mainly to carbonic anhydrase in red blood cells. It is slowly metabolised to N-de-ethyldorzolamide, which in turn is also stored in red blood cells. The very slow elimination (half-life >4 months) of both substances takes place via the renal route. However, the inhibition of carbonic anhydrase in red blood cells is moderate in the course of a topical treatment, avoiding systemic adverse effects. This review summarises the pharmacokinetic and pharmacodynamic properties of dorzolamide and its metabolite in eye tissues and in the systemic circulation.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know